Lupus anticoagulant activity as a thrombosis risk factor in lung adenocarcinoma patients

Annals of the New York Academy of Sciences

Volumn 1107, Issue , 2007, Pages 51-55

  De Meis, Ernesto ^a   Pinheiro, Vera R ^a   Loures, Maria Aparecida L ^a   Kotouc, Maria Mercedes ^a   Zamboni, Mauro M ^a   Guedes, Maria Tereza S ^a   Barros, Ailce S ^a   Castilho, Ilda Akemi M ^a   Levy, Roger A ^b  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

Author keywords

Adenocarcinoma; Cancer; Lupus anticoagulant; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 8; FIBRINOGEN; LUPUS ANTICOAGULANT;

ADULT; ANTIBODY BLOOD LEVEL; ANTICOAGULATION; CANCER PATIENT; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; THROMBOSIS; ADENOCARCINOMA; ARTICLE; LUNG TUMOR; METABOLISM; PATHOLOGY;

ADENOCARCINOMA; HUMANS; LUNG NEOPLASMS; LUPUS COAGULATION INHIBITOR; RISK FACTORS; THROMBOSIS;

EID: 34648840854     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1381.006     Document Type: Conference Paper

References (20)

1. KHORANA, A.A. 2003. Malignancy, thrombosis and Trousseau: the case for eponym. J. Thromb. Haemost. 1: 2463-2465.
2. FIMOGNARI, F.L., L. REPETTO, L. MORO, et al. 2005.Age, cancer and risk of venous thromboembolism. Crit. Rev. Oncol/Hematol. 55: 207-212.
3. ALIKAN, R., A.T. COHEN, S. COMBE, et al. 2004. Risk factor for thromboembolism in hospitalized patients with acute medical illness. Analysis of the MEDENOX study. Arch. Intern. Med. 164: 963-968.
4. TRIPODI, A. 2003. Levels of coagulation factors and venous thromboembolism. Haematology 88: 705-711.
5. BERTINA, R.M. 2003/2004. Elevated clotting factor levels and venous thrombosis. Pathophysiol. Haemost. Thromb. 33: 399-400.
6. OTTEN, H.M.B., J. MATHISJSSEN, H.T. TEN CATE, et al. 2004. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy. An underestimated phenomenon. Arch. Int. Med. 164: 190-194.
7. HADDAD, T.C. & E.W. GREENO. 2006. Chemotherapy-induced thrombosis. Thromb. Res. 118: 555-568.
8. PRANDONI, P., A. PICCIOLI & A. GIROLAMI. 1999. Cancer and venous thromboembolism: an overview. Haematology 84: 437-445.
9. RICKLES, F.R. & M.N. LEVINE. 2001. Epidemiology of thrombosis in cancer. Acta Haematol. 106: 6-12.
10. WHITE R.H., H.K. CHEW, H. ZHOU, et al. 2005. Incidence of thromboembolism in the year before the diagnosis of cancer in 528 693 adults. Arch. Int. Med. 165: 1782-1787.
11. CHEW, H.K., T. WUN, D. HARVEY, et al. 2006. Incidence of venous thromboembolism and its effects on survival among patients with common cancers. Arch. Int. Med. 166: 458-464.
12. LEVITAN, N., A. DOWLATI, S.C. REMICK, et al. 1999. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using MEDICARE claims data. Medicine 78: 285-291.
13. SøRENSEN, H.T., L. MELLEMKJæR, J.H. OLSEN, et al. 2000. Prognosis of cancer associated with venous thromboembolism. N. Engl. J. Med. 343: 1846-1850.
14. GOMEZ-PUERTA, J.A., R. CERVERA, G. ESPINOSA, et al. 2006. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin. Arthritis Rheum. 35: 322-332.
15. MIESBACH, W., I. SCHARRER & R. ASHERSON. 2006.Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies. Clin. Rheumatol. 25: 840-844.
16. GALLI, M., D. LUCIANI, G. BERTOLINI, et al. 2003. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101: 1827-1832.
17. ROBERTSON, B. & M. GREAVES. 2006. Antiphospholipid syndrome: an involving story. Blood Rev. 20: 201-212.
18. GENVRESSE, I., D. LUFTNER, E. SPATH-SCHWALBE, et al. 2002. Prevalence and clinical significance of anticardiolipin and anti-β2-glycoprotin-I antibodies in patients with non-Hodgkin's lymphoma. Eur. J. Haematol. 68: 84-90.
19. BAIREY, O., D. BLICKSTEIN, Y. MONSELISE, et al. 2006. Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma. Eur. J. Haematol. 76: 389-391.
20. BLOOM, J.W., S. OSANTO & R. ROSENDAAL. 2004. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J. Thromb. Haemost. 2: 1760-1765.